You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
Medtronic
Colorcon
Baxter

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

VABOMERE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Vabomere patents expire, and what generic alternatives are available?

Vabomere is a drug marketed by Rempex Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-nine patent family members in twenty-one countries.

The generic ingredient in VABOMERE is meropenem; vaborbactam. There are thirty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meropenem; vaborbactam profile page.

US ANDA Litigation and Generic Entry Outlook for Vabomere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 17, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for VABOMERE
Drug patent expirations by year for VABOMERE
Drug Prices for VABOMERE

See drug prices for VABOMERE

Generic Entry Opportunity Date for VABOMERE
Generic Entry Date for VABOMERE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VABOMERE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Biomedical Advanced Research and Development AuthorityPhase 1
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Phase 1

See all VABOMERE clinical trials

Pharmacology for VABOMERE

US Patents and Regulatory Information for VABOMERE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VABOMERE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2603514 132019000000049 Italy   Start Trial PRODUCT NAME: VABORBACTAM E/O UN SUO SALE E/O UN SUO IDRATO(VABOMERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1334, 20181122
2603514 122019000027 Germany   Start Trial PRODUCT NAME: KOMBINATION VON VABORBACTAM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON, UND MEROPENEM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON, INSBESONDERE MEROPENEMTRIHYDRAT; REGISTRATION NO/DATE: EU/1/18/1334 20181120
2603514 300978 Netherlands   Start Trial PRODUCT NAME: VABORBACTAM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1334 20181122
2603514 C201930023 Spain   Start Trial PRODUCT NAME: VABORBACTAM, Y/O UNA SAL Y/O UN HIDRATO DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1334; DATE OF AUTHORISATION: 20181120; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1334; DATE OF FIRST AUTHORISATION IN EEA: 20181120
2603514 2019C/514 Belgium   Start Trial PRODUCT NAME: UNE COMBINAISON DE VABORBACTAM, ET / OU D'UN DE SES SELS ET / OU HYDRATES, ET DU MEROPENEME, ET / OU DE SON SEL ET / OU DE SON HYDRATE, EN PARTICULIER DU MEROPENEME TRIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122
2603514 122019000026 Germany   Start Trial PRODUCT NAME: VABORBACTAM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/18/1334 20181120
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
Medtronic
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.